{"resourceType":"CodeSystem","id":"canshare-unpublished-concepts","meta":{"versionId":"1","lastUpdated":"2024-11-05T17:14:43.036+13:00"},"url":"http://canshare.co.nz/fhir/CodeSystem/snomed-unpublished","identifier":[{"system":"http://canshare.co.nz/fhir/NamingSystem/codesystems","value":"canshare-unpublished-concepts"}],"version":"1","name":"Canshare_unpublished_concepts","title":"Concepts that are not yet formally published","status":"active","publisher":"Te Aho o Te Kahu","contact":[{"telecom":[{"system":"email","value":"info@teaho.govt.nz"}]}],"caseSensitive":true,"content":"complete","concept":[{"code":"392611000210105","display":"BR Metastatic - cARBOplatin [2 AUC] and gemcitabine"},{"code":"392601000210108","display":"BR Metastatic - ribociclib"},{"code":"392591000210103","display":"LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under]"},{"code":"392581000210100","display":"LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under]"},{"code":"392571000210102","display":"LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under]"},{"code":"392561000210108","display":"LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]"},{"code":"392551000210105","display":"LEU - GMALL T-LBL 1/2004 triple prophylaxis"},{"code":"392541000210107","display":"LEU - GMALL T-LBL 1/2004 CYCLO/ARAC"},{"code":"392531000210104","display":"LEU - GMALL T-LBL 1/2004 VM26/ARAC"},{"code":"392521000210101","display":"LEU - GMALL T-LBL 1/2004 Reinduction"},{"code":"392511000210106","display":"LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years]"},{"code":"392501000210109","display":"LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years]"},{"code":"392491000210104","display":"LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years]"},{"code":"392481000210101","display":"LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years]"},{"code":"392471000210103","display":"LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk"},{"code":"392461000210109","display":"LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"392451000210106","display":"LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk"},{"code":"392441000210108","display":"LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"392431000210100","display":"LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years]"},{"code":"392421000210102","display":"LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3]"},{"code":"392411000210107","display":"LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis"},{"code":"392401000210105","display":"LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant]"},{"code":"392391000210107","display":"LEU - UKALL14 with RITUximab [not for transplant] Maintenance"},{"code":"392381000210105","display":"LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3]"},{"code":"392371000210108","display":"LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis"},{"code":"392361000210102","display":"LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction"},{"code":"392351000210100","display":"LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant]"},{"code":"392341000210103","display":"LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk"},{"code":"392331000210106","display":"LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"392321000210109","display":"LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk"},{"code":"392311000210104","display":"LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"392301000210101","display":"LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under]"},{"code":"392291000210100","display":"LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk"},{"code":"392281000210102","display":"LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"391941000210106","display":"LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk"},{"code":"391931000210103","display":"LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"391921000210100","display":"LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years]"},{"code":"391911000210105","display":"LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3]"},{"code":"391901000210108","display":"LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2]"},{"code":"391891000210107","display":"LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis"},{"code":"391881000210105","display":"LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction"},{"code":"391871000210108","display":"LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant]"},{"code":"391861000210102","display":"LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under]"},{"code":"391851000210100","display":"LEU - UKALL14 Consolidation [Cycle 1] [40 years and under]"},{"code":"391841000210103","display":"LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under]"},{"code":"391831000210106","display":"LEU - UKALL14 Phase 1 Induction [40 years and under]"},{"code":"391821000210109","display":"LEU ALL - UKALL14 [40 years and under]"},{"code":"391811000210104","display":"LEU - UKALL14 with RITUximab Consolidation [Cycle 4]"},{"code":"391801000210101","display":"LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3]"},{"code":"391791000210100","display":"LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2]"},{"code":"391781000210102","display":"LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis"},{"code":"391771000210104","display":"LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction"},{"code":"391761000210105","display":"LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction"},{"code":"391751000210107","display":"LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant]"},{"code":"391741000210109","display":"LEU - AIDA consolidation 3 [over 70 years]"},{"code":"391731000210101","display":"LEU - AIDA consolidation 2 [over 70 years]"},{"code":"391721000210103","display":"LEU - AIDA consolidation 1 [over 70 years]"},{"code":"391711000210108","display":"LEU - AIDA induction [over 70 years]"},{"code":"391701000210106","display":"LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years]"},{"code":"391691000210106","display":"LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"},{"code":"391681000210109","display":"LEU - Pethema LPA2005 maintenance [70 years and under] [low risk]"},{"code":"391671000210107","display":"LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk]"},{"code":"391661000210101","display":"LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk]"},{"code":"391621000210108","display":"LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk]"},{"code":"391601000210100","display":"LEU - Pethema LPA2005 induction [70 years and under] [low risk]"},{"code":"391591000210105","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk]"},{"code":"391581000210108","display":"LEU - Pethema LPA2005 maintenance [over 70 years] [low risk]"},{"code":"391571000210106","display":"LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk]"},{"code":"391561000210100","display":"LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk]"},{"code":"391551000210103","display":"LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk]"},{"code":"391541000210101","display":"LEU - Pethema LPA2005 induction [over 70 years] [low risk]"},{"code":"391531000210109","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk]"},{"code":"391521000210107","display":"LEU - Pethema LPA2005 maintenance [over 70 years] [high risk]"},{"code":"391511000210102","display":"LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk]"},{"code":"391501000210104","display":"LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk]"},{"code":"391491000210109","display":"LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk]"},{"code":"391481000210107","display":"LEU - Pethema LPA2005 induction [over 70 years] [high risk]"},{"code":"391471000210105","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk]"},{"code":"391461000210104","display":"GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC]"},{"code":"391451000210102","display":"GU URO Advanced - cISplatin and gemcitabine"},{"code":"391441000210100","display":"GU URO Advanced - cISplatin [split dose] and gemcitabine"},{"code":"391431000210108","display":"GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine"},{"code":"391421000210106","display":"GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin]"},{"code":"391411000210101","display":"LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk]"},{"code":"312741000210103","display":"LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk]"},{"code":"312731000210106","display":"LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk]"},{"code":"312721000210109","display":"LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk]"},{"code":"312711000210104","display":"LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk]"},{"code":"312701000210101","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk]"},{"code":"312691000210101","display":"LEU - Pethema LPA2005 maintenance [under 60 years] [high risk]"},{"code":"312681000210103","display":"LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk]"},{"code":"312671000210100","display":"LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk]"},{"code":"312661000210106","display":"LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk]"},{"code":"312651000210108","display":"LEU - Pethema LPA2005 induction [under 60 years] [high risk]"},{"code":"312631000210102","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk]"},{"code":"312621000210104","display":"LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk]"},{"code":"312611000210109","display":"LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk]"},{"code":"312601000210107","display":"LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk]"},{"code":"312591000210102","display":"LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk]"},{"code":"312581000210104","display":"LEU - Pethema LPA2005 induction [60 to 70 years] [high risk]"},{"code":"312571000210101","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk]"},{"code":"312561000210107","display":"LEU - UKALL14 Maintenance"},{"code":"312551000210109","display":"LEU - UKALL14 Consolidation [Cycle 4]"},{"code":"312541000210106","display":"LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years]"},{"code":"312531000210103","display":"LEU - UKALL14 Consolidation [Cycle 2]"},{"code":"312521000210100","display":"LEU - UKALL14 Consolidation [Cycle 1] [over 40 years]"},{"code":"312511000210105","display":"LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years]"},{"code":"312501000210108","display":"LEU - UKALL14 - Phase 2 Induction"},{"code":"312491000210103","display":"LEU - UKALL14 [over 40 years] - Phase 1 Induction"},{"code":"312481000210100","display":"LEU ALL - UKALL14 [over 40 years]"},{"code":"312471000210102","display":"LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"},{"code":"312461000210108","display":"LYM - DA-R-EPOCH LEVEL 6"},{"code":"312451000210105","display":"LYM - DA-R-EPOCH LEVEL 5"},{"code":"312441000210107","display":"LYM - DA-R-EPOCH LEVEL 4"},{"code":"312431000210104","display":"LYM - DA-R-EPOCH LEVEL 3"},{"code":"312421000210101","display":"LYM - DA-R-EPOCH LEVEL 2"},{"code":"312411000210106","display":"LYM - DA-R-EPOCH LEVEL minus 3"},{"code":"312401000210109","display":"LYM - DA-R-EPOCH LEVEL minus 2"},{"code":"312391000210106","display":"LYM - DA-R-EPOCH LEVEL minus 1"},{"code":"312381000210109","display":"LYM - DA-R-EPOCH LEVEL 1"},{"code":"312371000210107","display":"LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels]"},{"code":"312361000210101","display":"LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk"},{"code":"312351000210104","display":"LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"312341000210102","display":"LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk"},{"code":"312331000210105","display":"LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"312321000210108","display":"LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under]"},{"code":"312311000210103","display":"LEU - HyperCVAD POMP Maintenance"},{"code":"312301000210100","display":"LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk"},{"code":"312291000210104","display":"LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"312281000210101","display":"LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk"},{"code":"312271000210103","display":"LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"},{"code":"312261000210109","display":"LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years]"},{"code":"312251000210106","display":"SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W]"},{"code":"312241000210108","display":"SAR Ewing sarcoma - VAC, VC and IE [Q2W]"},{"code":"312231000210100","display":"SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"},{"code":"312221000210102","display":"SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"},{"code":"312211000210107","display":"SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk]"},{"code":"312201000210105","display":"SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk]"},{"code":"312191000210108","display":"SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk]"},{"code":"312181000210106","display":"SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk]"},{"code":"312171000210109","display":"SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk]"},{"code":"312161000210103","display":"SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk]"},{"code":"312151000210101","display":"SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]"},{"code":"312141000210104","display":"SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W]"},{"code":"312131000210107","display":"SAR Ewing sarcoma - VAC, VC and IE [Q3W]"},{"code":"312121000210105","display":"SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W]"},{"code":"312111000210100","display":"SAR - IE [IFOSfamide and etoposide][Q3W]"},{"code":"312101000210102","display":"SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W]"},{"code":"312091000210109","display":"SAR Ewing sarcoma - VDC, VC and IE [Q3W]"},{"code":"312081000210107","display":"SAR - MA [metHOTREXATe and DOXOrubicin]"},{"code":"312071000210105","display":"SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"},{"code":"312061000210104","display":"SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"},{"code":"312051000210102","display":"PCN MM - pamidronate 90mg Q4W"},{"code":"312041000210100","display":"LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2]"},{"code":"312031000210108","display":"LEU ALL precursor B-cell - blinatumomab [CNS3]"},{"code":"312021000210106","display":"CRC REC Locally advanced - dostarlimab"},{"code":"312011000210101","display":"CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles"},{"code":"312001000210103","display":"CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles"},{"code":"311991000210101","display":"CRC - CAPOX 6 cycles"},{"code":"311981000210103","display":"CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy"},{"code":"311971000210100","display":"CRC Metastatic - irinotecan [Q3W] dose reduced"},{"code":"311961000210106","display":"CRC Metastatic - CETUximab Q2W"},{"code":"311951000210108","display":"CRC Metastatic - trifluridine/tipiracil and beVACizumab"},{"code":"311941000210105","display":"CRC Metastatic - trifluridine/tipiracil"},{"code":"311931000210102","display":"CRC Metastatic - pembrolizumab Q6W [flat dosing]"},{"code":"311921000210104","display":"CRC Locally advanced - ipilimumab and nivolumab"},{"code":"311911000210109","display":"CRC Metastatic - pembrolizumab Q3W [flat dosing]"},{"code":"311901000210107","display":"CRC Metastatic - CETUximab [Q2W] and encorafenib"},{"code":"311891000210106","display":"CRC Metastatic - CETUximab [Q2W] and daBRAFEnib"},{"code":"311881000210109","display":"LEU - AIDA consolidation 3 [70 years and under]"},{"code":"311871000210107","display":"LEU - AIDA consolidation 2 [70 years and under]"},{"code":"311861000210101","display":"LEU - AIDA consolidation 1 [70 years and under]"},{"code":"311851000210104","display":"LEU - AIDA induction [70 years and under]"},{"code":"311841000210102","display":"LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under]"},{"code":"311831000210105","display":"LEU - arsenic trioxide and tretinoin consolidation [AML17]"},{"code":"311821000210108","display":"LEU - arsenic trioxide and tretinoin induction [AML17]"},{"code":"311811000210103","display":"LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17]"},{"code":"311801000210100","display":"LEU - APML4 maintenance [61 to 70 years]"},{"code":"311791000210104","display":"LEU - APML4 consolidation 2 [61 to 70 years]"},{"code":"311781000210101","display":"LEU - APML4 consolidation 1 [61 to 70 years]"},{"code":"311771000210103","display":"LEU - APML4 induction [61 to 70 years]"},{"code":"311761000210109","display":"LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years]"},{"code":"311751000210106","display":"LEU - APML4 maintenance [over 70 years]"},{"code":"311741000210108","display":"LEU - APML4 consolidation 2 [over 70 years]"},{"code":"311721000210102","display":"LEU - APML4 consolidation 1 [over 70 years]"},{"code":"311711000210107","display":"LEU - APML4 induction [over 70 years]"},{"code":"311701000210105","display":"LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years]"},{"code":"311691000210105","display":"LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk]"},{"code":"311681000210108","display":"LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk]"},{"code":"311671000210106","display":"LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk]"},{"code":"311661000210100","display":"LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk]"},{"code":"311651000210103","display":"LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk]"},{"code":"311641000210101","display":"LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk]"},{"code":"311631000210109","display":"LEU HCL - cladribine and RITUximab"},{"code":"311621000210107","display":"LEU - arsenic trioxide and tretinoin consolidation [standard risk]"},{"code":"311611000210102","display":"LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk]"},{"code":"311601000210104","display":"LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk]"},{"code":"311591000210109","display":"LEU - APML4 maintenance [60 years and under]"},{"code":"311581000210107","display":"LEU - APML4 consolidation 2 [60 years and under]"},{"code":"311571000210105","display":"LEU - APML4 consolidation 1 [60 years and under]"},{"code":"311561000210104","display":"LEU - APML4 induction [60 years and under]"},{"code":"311551000210102","display":"LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under]"},{"code":"311541000210100","display":"LEU - UKALL14 with daSATinib Maintenance"},{"code":"311531000210108","display":"LEU - UKALL14 with daSATinib Consolidation [Cycle 4]"},{"code":"311521000210106","display":"LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3]"},{"code":"311511000210101","display":"LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2]"},{"code":"311501000210103","display":"LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis"},{"code":"311491000210108","display":"LEU - UKALL14 with daSATinib Phase 2 Induction"},{"code":"311481000210106","display":"LEU - UKALL14 with daSATinib Phase 1 Induction"},{"code":"311471000210109","display":"LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib"},{"code":"311461000210103","display":"LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance"},{"code":"311451000210101","display":"LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3]"},{"code":"311441000210104","display":"LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis"},{"code":"311431000210107","display":"LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction"},{"code":"311421000210105","display":"LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant]"},{"code":"311411000210100","display":"LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation"},{"code":"311401000210102","display":"LYM - R-MPV alternating with R-MV"},{"code":"311391000210100","display":"LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine"},{"code":"311381000210102","display":"LYM - EA [etoposide and cytarabine]"},{"code":"311371000210104","display":"LYM - MT-R"},{"code":"311361000210105","display":"LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine]"},{"code":"311351000210107","display":"LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis]"},{"code":"311341000210109","display":"LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction"},{"code":"311331000210101","display":"LEU CLL Relapsed - aLEMTUzumab [subcut]"},{"code":"311321000210103","display":"LEU CLL - venetoclax and oBINUTUZumab"},{"code":"311311000210108","display":"LEU CLL - RITUximab and bendamustine"},{"code":"311301000210106","display":"LEU CLL Relapsed - aLEMTUzumab [IV]"},{"code":"311291000210107","display":"LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4]"},{"code":"311281000210105","display":"LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant]"},{"code":"311271000210108","display":"LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2]"},{"code":"311261000210102","display":"LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis"},{"code":"311251000210100","display":"LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant]"},{"code":"311241000210103","display":"LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction"},{"code":"311231000210106","display":"LEU - dexamethasone 6 mg/m2 days 1 to 5"},{"code":"311221000210109","display":"LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant]"},{"code":"311211000210104","display":"LYM - oBINUTUZumab maintenance"},{"code":"311201000210101","display":"LYM - bendamustine and oBINUTUZumab"},{"code":"311191000210103","display":"LYM NHL B-cell - bendamustine and oBINUTUZumab"},{"code":"311181000210100","display":"LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase]"},{"code":"311171000210102","display":"LEU CLL - venetoclax and RITUximab"},{"code":"311161000210108","display":"LEU - imatinib 600"},{"code":"311151000210105","display":"LEU - imatinib 400"},{"code":"311141000210107","display":"LEU CML - imatinib"},{"code":"311131000210104","display":"LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab"},{"code":"311121000210101","display":"LEU - UKALL60+ Maintenance"},{"code":"311111000210106","display":"LEU - UKALL60+ Consolidation"},{"code":"311101000210109","display":"LEU - UKALL60+ Phase 2 Induction"},{"code":"311091000210102","display":"LEU - UKALL60+ Phase 1 Induction"},{"code":"311081000210104","display":"LEU ALL - UKALL60+ [non-intensive]"},{"code":"311071000210101","display":"LEU - UKALL60+ with daSATinib Maintenance"},{"code":"311061000210107","display":"LEU - UKALL60+ with daSATinib Consolidation"},{"code":"311051000210109","display":"LEU - UKALL60+ with daSATinib Phase 2 Induction"},{"code":"311041000210106","display":"LEU - UKALL60+ with daSATinib Phase 1 Induction"},{"code":"311031000210103","display":"LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib"},{"code":"311021000210100","display":"LEU - UKALL60+ with imatinib Maintenance"},{"code":"311011000210105","display":"LEU - UKALL60+ with imatinib Consolidation"},{"code":"311001000210108","display":"LEU - UKALL60+ with imatinib Phase 2 Induction"},{"code":"310991000210109","display":"LEU - UKALL60+ with imatinib Phase 1 Induction"},{"code":"310981000210107","display":"LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5"},{"code":"310971000210105","display":"LEU ALL BCR-ABL1+ - UKALL60+ with imatinib"},{"code":"310961000210104","display":"LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"},{"code":"310951000210102","display":"LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction"},{"code":"310941000210100","display":"LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation"},{"code":"310931000210108","display":"LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years]"},{"code":"303631000210108","display":"LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years]"},{"code":"303621000210106","display":"LEU - High dose cytarabine and midostaurin consolidation [under 60 years]"},{"code":"303611000210101","display":"LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years]"},{"code":"303601000210103","display":"LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years]"},{"code":"303591000210108","display":"LEU - Midostaurin maintenance"},{"code":"303581000210106","display":"LEU - High dose cytarabine and midostaurin consolidation [60 years and over]"},{"code":"303571000210109","display":"LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over]"},{"code":"303561000210103","display":"LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over]"},{"code":"303551000210101","display":"LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation"},{"code":"303541000210104","display":"LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction"},{"code":"303531000210107","display":"LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation"},{"code":"303521000210105","display":"LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide]"},{"code":"303511000210100","display":"LYM - procarbazine [100 mg daily for 5 days]"},{"code":"303501000210102","display":"LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over]"},{"code":"303491000210107","display":"LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over]"},{"code":"303481000210105","display":"LYM NHL B-cell - RITUximab and bendamustine"},{"code":"303471000210108","display":"LYM NHL B-cell - RITUximab Maintenance Q8W"},{"code":"303461000210102","display":"LYM NHL B-cell - RITUximab Q1W"},{"code":"303451000210100","display":"GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab"},{"code":"303441000210103","display":"GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab"},{"code":"265711000210103","display":"Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation"},{"code":"265701000210100","display":"Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation"},{"code":"265691000210100","display":"Desmoid fibromatosis - metHOTREXATe and vinBLASTine"},{"code":"265681000210102","display":"SAR STS Metastatic - DOCEtaxel and gemcitabine 900"},{"code":"265671000210104","display":"SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis]"},{"code":"265661000210105","display":"SAR STS Advanced - trabectedin"},{"code":"265651000210107","display":"SAR STS Advanced - pAZOPanib"},{"code":"265641000210109","display":"SAR STS Advanced - IFOSFamide [3-day]"},{"code":"265631000210101","display":"SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W]"},{"code":"265621000210103","display":"SAR - IE [IFOSfamide and etoposide][Q2W]"},{"code":"265611000210108","display":"SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W]"},{"code":"265601000210106","display":"SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W]"},{"code":"265591000210101","display":"SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000"},{"code":"265581000210103","display":"SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000"},{"code":"265571000210100","display":"SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin"},{"code":"265561000210106","display":"SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan"},{"code":"265551000210108","display":"SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide]"},{"code":"265541000210105","display":"SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin"},{"code":"265531000210102","display":"LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"},{"code":"265521000210104","display":"Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide"},{"code":"265411000210105","display":"GU Renal cell Metastatic - aXITinib and avelumab [flat dose]"},{"code":"265401000210108","display":"GU - nivolumab maintenance Q2W [flat dosing]"},{"code":"265391000210105","display":"GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing]"},{"code":"265381000210108","display":"GU - nivolumab maintenance Q4W [flat dosing]"},{"code":"265371000210106","display":"GU - nivolumab and ipilimumab induction"},{"code":"265361000210100","display":"GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing]"},{"code":"265351000210103","display":"GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing]"},{"code":"265341000210101","display":"GU Renal cell Metastatic - leNVAtinib and everolimus"},{"code":"265331000210109","display":"GU Bladder Urothelial - gemcitabine [low dose] chemoradiation"},{"code":"265321000210107","display":"GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense"},{"code":"264811000210106","display":"LEU - daSATinib 140"},{"code":"264801000210109","display":"LEU - daSATinib 100"},{"code":"264791000210105","display":"LEU CML - daSATinib"},{"code":"264781000210108","display":"LEU HCL - cladribine"},{"code":"264771000210106","display":"PCN MM - lenalidomide and dexamethasone"},{"code":"264761000210100","display":"GYN VUL Advanced - ciSplatin [Q1W] chemoradiation"},{"code":"264751000210103","display":"LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine"},{"code":"264741000210101","display":"LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine"},{"code":"264731000210109","display":"SAR Ewing sarcoma Relapsed - irinotecan and temozolomide"},{"code":"264721000210107","display":"Desmoid fibromatosis - metHOTREXATe and vinORELBine"},{"code":"264411000210109","display":"LEU CLL - chlorambucil and oBINUTUZumab"},{"code":"264401000210107","display":"LEU - nilotinib 300"},{"code":"264391000210109","display":"LEU - nilotinib 400"},{"code":"264381000210107","display":"LEU CML - nilotinib"},{"code":"264371000210105","display":"CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2"},{"code":"264361000210104","display":"LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide]"},{"code":"264351000210102","display":"LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide]"},{"code":"264341000210100","display":"LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine]"},{"code":"264331000210108","display":"LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenstr√∂m macroglobulinema]"},{"code":"264321000210106","display":"LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone]"},{"code":"264011000210104","display":"PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone"},{"code":"264001000210101","display":"Myelodysplastic syndrome - azacitidine [7 day]"},{"code":"263991000210105","display":"Myelodysplastic syndrome - azacitidine [5 day]"},{"code":"263981000210108","display":"LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over]"},{"code":"263971000210106","display":"CNS GBM Recurrent - beVACizumab and lomustine"},{"code":"263961000210100","display":"CNS GBM Recurrent - beVACizumab Q2W"},{"code":"263951000210103","display":"CNS GBM Recurrent - beVACizumab Q3W"},{"code":"263941000210101","display":"CNS GLI Recurrent - temozolomide [high grade]"},{"code":"263931000210109","display":"CNS - temozolomide following chemoradiation"},{"code":"263921000210107","display":"CNS - temozolomide chemoradiation"},{"code":"60091000210105","display":"GYN - cARBOplatin and PACLItaxel [following chemoradiation]"},{"code":"60081000210108","display":"GYN - cISplatin chemoradiation"},{"code":"60071000210106","display":"GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"},{"code":"60061000210100","display":"GYN OV Recurrent - topotecan"},{"code":"60051000210103","display":"GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]"},{"code":"60041000210101","display":"GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation"},{"code":"60031000210109","display":"GYN OV Recurrent - topotecan and beVACizumab Q4W"},{"code":"60021000210107","display":"GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk]"},{"code":"60011000210102","display":"GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk]"},{"code":"60001000210104","display":"GYN OV Low grade serous carcinoma - letrozole maintenance"},{"code":"59991000210107","display":"GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing]"},{"code":"59981000210105","display":"GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous]"},{"code":"59971000210108","display":"GYN OV Recurrent - etoposide oral"},{"code":"59961000210102","display":"GYN OV Recurrent - gemcitabine"},{"code":"59951000210100","display":"GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride"},{"code":"59941000210103","display":"GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab"},{"code":"59931000210106","display":"GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation"},{"code":"59921000210109","display":"GYN CX Locally advanced - cISplatin [Q1W] chemoradiation"},{"code":"59911000210104","display":"GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk]"},{"code":"59901000210101","display":"LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing]"},{"code":"496201000210103","display":"Malignancy, direct spread to cervix and/or vagina"},{"code":"496211000210101","display":"Cervix specimen from partial hysterectomy"},{"code":"496231000210108","display":"Cervix specimen from total hysterectomy"},{"code":"496241000210100","display":"Polyp specimen"},{"code":"496191000210100","display":"Endocervical adenocarcinoma, superficially invasive"},{"code":"497441000210104","display":"SACT regimen type"},{"code":"497451000210101","display":"Prescribed dose unit"},{"code":"497461000210103","display":"Administered dose unit"},{"code":"495991000210106","display":"Tumour width"},{"code":"496001000210105","display":"Tumour depth"},{"code":"495981000210109","display":"Tumour length"},{"code":"7283002","display":"Base of tongue"},{"code":"1340143004","display":"Intrahepatic bile duct"},{"code":"505941000210108","display":"Extra-adrenal paraganglioma primary"},{"code":"507401000210108","display":"Histopathology request"},{"code":"507411000210105","display":"Histopathology report"}]}